



Alirocumab

Revised: December 3, 2018.

CASRN: 1245916-14-6

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of alirocumab during breastfeeding. Because alirocumab is a large protein molecule with a molecular weight of 146,000, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Until more data become available, alirocumab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Alirocumab

CAS Registry Number

1245916-14-6

Drug Class

Breast Feeding

Lactation

Antibodies, Monoclonal

Anticholesteremic Agents

Antilipemic Agents